Federal Register / Vol. 82, No. 186 / Wednesday, September 27, 2017 / Notices 45031 

Comments in Response to the 60 Day 

Federal Register Notice 

A 60-day notice was published in the 

Federal Register in Vol. 82, No. 117, pg. 

28068 on June 20, 2017. No comments 

were received. 

Annual Burden Estimates 

ACL estimates the burden of this 

collection of information as follows: 56 

State Units on Aging (SUA) respond 

semi-annually which have an average 

estimated burden of 2 hours per grantee 

for a total of 112 hours per submission. 

The proposed data collection tool may 

be found on the ACL Web site for 

review at: https://www.acl.gov/aboutacl/public-input. 

Respondent/data collection activity Number of 

respondents 

Responses 

per 

respondent 

Hours per 

response 

Total annual 

burden hours 

Title III Supplemental Form to the Financial Status Report ............................ 56 2/yr 2 224 

Total .......................................................................................................... 56 2/yr 2 224 

Dated: September 19, 2017. 

Mary Lazare, 

Principal Deputy Administrator. 

[FR Doc. 2017–20666 Filed 9–26–17; 8:45 am] 

BILLING CODE 4154–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2017–N–0001] 

Advisory Committee; National 

Mammography Quality Assurance 

Advisory Committee; Renewal 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; renewal of advisory 

committee. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 

renewal of the National Mammography 

Quality Assurance Advisory Committee 

by the Commissioner of Food and Drugs 

(the Commissioner). The Commissioner 

has determined that it is in the public 

interest to renew the National 

Mammography Quality Assurance 

Advisory Committee for an additional 2 

years beyond the charter expiration 

date. The new charter will be in effect 

until July 7, 2019. 

DATES: Authority for the National 

Mammography Quality Assurance 

Advisory Committee will expire on July 

7, 2017, unless the Commissioner 

formally determines that renewal is in 

the public interest. 

FOR FURTHER INFORMATION CONTACT: Sara 

Anderson, Office of Device Evaluation, 

Center for Devices and Radiological 

Health, Food and Drug Administration, 

10903 New Hampshire Ave., Bldg. 66, 

Rm. G616, Silver Spring, MD 20993– 

0002, 301–796–7047, Sara.Anderson@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: Pursuant 

to 41 CFR 102–3.65 and approval by the 

Department of Health and Human 

Services (HHS) pursuant to 45 CFR part 

11 and by the General Services 

Administration, FDA is announcing the 

renewal of the National Mammography 

Quality Assurance Advisory Committee 

(Committee). The Committee is a nondiscretionary Federal advisory 

committee established to provide advice 

to the Commissioner. The HHS 

Secretary and, by delegation, the 

Assistant Secretary for the Office of 

Public Health and Science and the 

Commissioner are charged with the 

administration of the Federal Food, 

Drug, and Cosmetic Act and various 

provisions of the Public Health Service 

Act. The Mammography Quality 

Standards Act of 1992 amends the 

Public Health Service Act to establish 

national uniform quality and safety 

standards for mammography facilities. 

The Committee advises the HHS 

Secretary and, by delegation, the 

Commissioner in discharging their 

responsibilities with respect to 

establishing a mammography facilities 

certification program. The Committee 

shall advise FDA on: 

• Developing appropriate quality 

standards and regulations for 

mammography facilities; 

• Developing appropriate standards 

and regulations for bodies accrediting 

mammography facilities under this 

program; 

• Developing regulations with respect 

to sanctions; 

• Developing procedures for 

monitoring compliance with standards; 

• Establishing a mechanism to 

investigate consumer complaints; 

• Reporting new developments 

concerning breast imaging which should 

be considered in the oversight of 

mammography facilities; 

• Determining whether there exists a 

shortage of mammography facilities in 

rural and health professional shortage 

areas and determining the effects of 

personnel on access to the services of 

such facilities in such areas; 

• Determining whether there will 

exist a sufficient number of medical 

physicists after October 1, 1999; and 

• Determining the costs and benefits 

of compliance with these requirements. 

The Committee shall consist of a core 

of 15 members, including the Chair. 

Members and the Chair are selected by 

the Commissioner or designee from 

among physicians, practitioners, and 

other health professionals, whose 

clinical practice, research 

specialization, or professional expertise 

includes a significant focus on 

mammography. Members will be invited 

to serve for overlapping terms of up to 

4 years. Almost all non-Federal 

members of this Committee serve as 

Special Government Employees. The 

core of voting members shall include at 

least four individuals from among 

national breast cancer or consumer 

health organizations with expertise in 

mammography, and at least two 

practicing physicians who provide 

mammography services. In addition to 

the voting members, the Committee 

shall include two nonvoting industry 

representatives who have expertise in 

mammography equipment. The 

Committee may include one technically 

qualified member, selected by the 

Commissioner or designee, who is 

identified with consumer interests. 

Further information regarding the 

most recent charter and other 

information can be found at https://

www.fda.gov/AdvisoryCommittees/ 

CommitteesMeetingMaterials/RadiationEmittingProducts/National

MammographyQualityAssurance

AdvisoryCommittee/ucm520365.htm or 

by contacting the Designated Federal 

Officer (see FOR FURTHER INFORMATION

CONTACT). In light of the fact that no 

change has been made to the Committee 

name or description of duties, no 

amendment will be made to 21 CFR 

14.100. 

This document is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app.). For general information 

related to FDA advisory committees, 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
45032 Federal Register / Vol. 82, No. 186 / Wednesday, September 27, 2017 / Notices 

please visit us at https://www.fda.gov/ 

AdvisoryCommittees/default.htm. 

Dated: September 22, 2017. 

Anna K. Abram, 

Deputy Commissioner for Policy, Planning, 

Legislation, and Analysis. 

[FR Doc. 2017–20683 Filed 9–26–17; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Ryan White HIV/AIDS Program, Part F 

AIDS Education and Training Centers 

AGENCY: Health Resources and Services 

Administration, HHS. 

ACTION: Notice of non-competitive, 

HRSA-initiated, Secretary’s Minority 

AIDS Initiative Fund (SMAIF) 

supplemental funding award: Fiscal 

Year (FY) 2017 Ryan White HIV/AIDS 

Program (RWHAP) AIDS Education and 

Training Centers (AETC) to the National 

Clinician Consultation Center (NCCC) at 

the University of California, San 

Francisco. 

SUMMARY: This non-competitive 

supplemental funding award will 

provide a phone consultation line 

staffed by clinicians dedicated to 

providing technical support and realtime clinical consultation to health 

professionals who treat people living 

with HIV (PLWH) who are coinfected 

with the hepatitis C virus (HCV). 

FOR FURTHER INFORMATION CONTACT: Ms. 

Sherrillyn Crooks, Chief, HIV Education 

Branch, HIV/AIDS Bureau, Health 

Resources and Services Administration, 

5600 Fishers Lane, 09N09, Rockville, 

MD 20857, Phone: (301) 443–7662, 

Email: scrooks@hrsa.gov. 

SUPPLEMENTARY INFORMATION: 

Intended Recipient of the Award: The 

University of California, San Francisco. 

Amount of Non-Competitive Award: 

$200,000. 

Period of Funding: July 1, 2017, 

through June 30, 2018. 

CFDA Number: 93.145. 

Authority: The Consolidated 

Appropriations Act, 2017 (Pub. L. 115– 

31), Division H, Title II. 

Justification 

HRSA’s SMAIF HIV/HCV initiatives 

seek to improve the prevention, 

screening, care, treatment, and cure of 

HCV in areas affected by HIV/HCV 

coinfection, particularly in 

disproportionately affected low-income, 

uninsured and underserved racial and 

ethnic minority populations in the 

United States. Despite the fact that HIV 

treatment outcomes continue to improve 

among PLWH, HIV/HCV coinfection 

remains a major concern with 

approximately one quarter of PLWH 

also coinfected with HCV. 

The University of California, San 

Francisco’s NCCC is funded under the 

RWHAP AETC Program, which 

comprises a network of three national 

centers and eight regional centers (with 

more than 130 local affiliated sites) that 

conduct targeted, multidisciplinary 

education, training, and technical 

assistance to health care providers who 

treat PLWH. The NCCC provides 

nationwide expert technical support, 

and clinical consultation services to 

health professionals who treat PLWH. 

Supplemental funding will enable the 

NCCC to leverage its existing 

infrastructure to add an HIV/HCV phone 

consultation line to deliver immediate 

clinical consultation and education 

services to RWHAP clinical providers 

funded through the SMAIF HIV/HCV 

initiatives and to clinical providers 

nationwide. Clinical providers will 

receive guidance based on up-to-date 

clinical HCV guidelines. Subject to the 

availability of funds and the recipient’s 

satisfactory performance, up to $200,000 

will also be awarded in FY18 (budget 

period July 1, 2018 through June 30, 

2019) and FY19 (budget period July 1, 

2019 through June 30, 2020). 

Denial of this request will prevent 

RWHAP clinical providers from 

achieving the goals of the SMAIF HIV/ 

HCV initiative and from gaining critical 

and immediate access to a national 

network of HIV/HCV resources, 

including clinical experts who would 

provide education and technical 

assistance that meets the unique needs 

of this initiative. 

Dated: September 14, 2017. 

George Sigounas, 

Administrator. 

[FR Doc. 2017–20687 Filed 9–26–17; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Request for Comments on the Draft 

Department Strategic Plan for FY 

2018–2022 

AGENCY: Office of the Secretary, Office 

of the Assistant Secretary for Planning 

and Evaluation, Health and Human 

Services. 

ACTION: Request for Comments on the 

Draft Strategic Plan FY 2018–2022. 

SUMMARY: The Department of Health and 

Human Services (HHS) is seeking public 

comment on its draft Strategic Plan for 

Fiscal Years 2018–2022. 

DATES: Submit comments on or before 

October 26, 2017. 

ADDRESSES: Written comments can be 

provided by email, fax or U.S. mail. 

Email: HHSPlan@hhs.gov. 

Fax: (202) 690–5882. 

Mail: U.S. Department of Health and 

Human Services, Office of the Assistant 

Secretary for Planning and Evaluation, 

Strategic Planning Team, Attn: Strategic 

Plan Comments, 200 Independence 

Avenue SW., Room 415F, Washington, 

DC 20201. 

FOR FURTHER INFORMATION CONTACT: 

Sarah Potter, (202) 260–6518. 

SUPPLEMENTARY INFORMATION: The draft 

Department of Health and Human 

Services Strategic Plan FY 2018–2022 is 

provided as part of the strategic 

planning process under the Government 

Performance and Results Modernization 

Act of 2010 (GPRA–MA) (Pub. L. 111– 

352) to ensure that Agency stakeholders 

are given an opportunity to comment on 

this plan. 

This document articulates how the 

Department will achieve its mission 

through five strategic goals. These five 

strategic goals are (1) Reform, 

Strengthen, and Modernize the Nation’s 

Health Care System, (2) Protect the 

Health of Americans Where They Live, 

Learn, Work, and Play, (3) Strengthen 

the Economic and Social Well-Being of 

Americans across the Lifespan, (4) 

Foster Sound, Sustained Advances in 

Sciences, and (5) Promote Effective and 

Efficient Management and Stewardship. 

Each goal is supported by objectives and 

strategies. 

The strategic planning consultation 

process is an opportunity for the 

Department to refine and strengthen the 

HHS Strategic Plan FY 2018–2022. The 

Department has made significant 

progress in its strategic and performance 

planning efforts. As we build on this 

progress we look forward to receiving 

your comments by October 26, 2017. 

The text of the draft HHS Strategic Plan 

FY 2018–2022 is available through the 

Department of Health and Human 

Services Web site at https://

www.hhs.gov/draft-strategic-plan. 

For comparison purposes, the current 

HHS Strategic Plan FY 2014–2018 can 

be viewed at https://www.hhs.gov/ 

about/strategic-plan/index.html. 

For those who may not have Internet 

access, a hard copy can be requested 

from the contact point, Sarah Potter, 

(202) 260–6518. 


asabaliauskas on DSKBBXCHB2PROD with NOTICES